Membrane proteins

AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics

Retrieved on: 
Tuesday, July 20, 2021
Health, Chemicals, Plastics, Manufacturing, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Membrane proteins, Biology, Electrophysiology, Integral membrane proteins, Protein families, Sodium channels, Cell communication, Ion channel, Venom, Migraine, Channel blocker

It has a variety of causes and negatively impacts the quality of life of those who are affected.

Key Points: 
  • It has a variety of causes and negatively impacts the quality of life of those who are affected.
  • The natural world is full of venomous creatures whose venoms are full of potential drug candidates, for treating conditions such as diabetes, pain, and cancer.
  • Isolation of certain sodium channel blocking peptides from spider venoms have been shown to function as potential therapeutics for pain alleviation.
  • Targeting the voltage-gated ion channels may yield useful treatments in an array of disorders, including pain, migraines, epilepsy, neurological disorders, and more.

Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials

Retrieved on: 
Thursday, June 17, 2021
Research, Hospitals, Clinical trials, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Membrane proteins, Proteins, Programmed cell death, Apoptosis, Oncogenes, Bcl-2 family, MCL1, Bcl-2

Anji Pharma (Anji), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the programs MCL1 inhibitors through clinical development.

Key Points: 
  • Anji Pharma (Anji), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the programs MCL1 inhibitors through clinical development.
  • MCL1 is a member of the Bcl-2 family, normally acting as a brake on the apoptosis pathway.
  • In many human cancers, the Mcl-1 gene is highly amplified, shifting the balance from pro- to anti-apoptotic signals and promoting cancer cell survival and tumor formation.
  • The MCL1 program is one of several programs pursued by the Center for Development of Therapeutics (CDoT) at the Broad Institute.

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Retrieved on: 
Thursday, June 10, 2021
Integral membrane proteins, Membrane proteins, Transmembrane proteins, Single-pass transmembrane proteins, Transmembrane receptors, Neuropilin 2, Neuropilin, Semaphorin, E-selectin, aTyr Pharma

The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.

Key Points: 
  • The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.
  • Class 3 Semaphorins are an important set of NRP2 ligands, with recent data implicating their role in sustaining chronic inflammation.
  • Details of the abstract and poster presentation are as follows:
    The poster is also available on the aTyr website.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

Retrieved on: 
Tuesday, October 13, 2020
Branches of biology, Medical specialties, Membrane proteins, Sodium channels, Electrophysiology, Epithelial sodium channel, Cystic fibrosis

IONIS-ENAC-2.5Rx is an investigational antisense medicine designed to reduce the expression of ENaC in the lung.

Key Points: 
  • IONIS-ENAC-2.5Rx is an investigational antisense medicine designed to reduce the expression of ENaC in the lung.
  • ENaC is believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.
  • Data from the Phase 1 study will be presented via e-poster at the 2020 North American Cystic Fibrosis Conference , which will hold virtual sessions and discussions Oct. 21-23.
  • Cystic fibrosis is a life-threatening disease affecting approximately 30,000 people in the U.S. and about 70,000 worldwide.

NTHU Unveils Ray of Hope for Improving Dementia Treatment

Retrieved on: 
Tuesday, October 6, 2020
Health, Other Health, Clinical trials, Research, Science, Biotechnology, Membrane proteins, Branches of biology, Proteins, Solute carrier family, Integral membrane proteins, Neurotransmitter transporters, Transport proteins, Ion transporter, Cotransporter

The teams research finding has been published in the August issue of Science Advances.

Key Points: 
  • The teams research finding has been published in the August issue of Science Advances.
  • Human phosphate transporter (hPiT) is an important membrane protein for transporting phosphate and sodium ions into brain cells.
  • Sun said that analyzing the human phosphate transporter and locating the site of the patients variants are important in finding a treatment for brain calcification.
  • The first step in analyzing the molecular structure of membrane protein is to cultivate the membrane protein crystal.

Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis

Retrieved on: 
Tuesday, August 11, 2020
Infectious diseases, Genetics, Clinical trials, Cardiology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Branches of biology, Membrane proteins, Ion channels, Histology, Mucociliary clearance, Respiratory system, Cystic fibrosis, Epithelial sodium channel, Arrowhead Pharmaceuticals

ARO-ENaC utilizes Arrowheads proprietary Targeted RNAi Molecule (TRiM) platform and is the companys first inhaled RNAi candidate to target pulmonary epithelium.

Key Points: 
  • ARO-ENaC utilizes Arrowheads proprietary Targeted RNAi Molecule (TRiM) platform and is the companys first inhaled RNAi candidate to target pulmonary epithelium.
  • Our preclinical work on ARO-ENaC has been highly promising and we are eager to see how these results translate to humans.
  • In patients with CF, dysfunction in the cystic fibrosis transmembrane conductance regulator (CFTR) causes increased ENaC activity which contributes to airway dehydration and reduced mucociliary transport.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

Retrieved on: 
Tuesday, July 28, 2020
Technology, Infectious diseases, Genetics, Clinical trials, Nanotechnology, Cardiology, Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Sodium channels, Ion channels, Membrane proteins, RTT, Electrophysiology, Epithelial sodium channel, Cystic fibrosis, Mucociliary clearance, ENAC, Arrowhead Pharmaceuticals, SCNN1B

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00 PM EDT on ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00 PM EDT on ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF).
  • The live webinar and replay may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
  • ARO-ENaC is designed to reduce activity of the epithelial sodium channel alpha subunit in the airways of the lung.
  • In patients with CF, CFTR dysfunction causes increased ENaC activity, which contributes to airway dehydration and reduced mucociliary transport.

Insights on the H1 2020 Pipeline Review for P2X Purinoceptor 3 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 23, 2020
Health, Pharmaceutical, Branches of biology, Proteins, Ion channels, Membrane proteins, P2RX3, P2X purinoreceptor, P2RX7, P2RX6

The "P2X Purinoceptor 3 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "P2X Purinoceptor 3 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'P2X Purinoceptor 3 - Pipeline Review, H1 2020'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 13 molecules.
  • P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene.
  • The report 'P2X Purinoceptor 3 - Pipeline Review, H1 2020' outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

Retrieved on: 
Thursday, July 9, 2020
General Health, Pharmaceutical, Genetics, Health, Branches of biology, Sodium channels, Ion channels, Membrane proteins, RTT, Electrophysiology, Epithelial sodium channel, Cystic fibrosis, Arrowhead Pharmaceuticals, ENAC, Mucociliary clearance, Cilium

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020, at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020, at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF).
  • The webinar may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
  • ARO-ENaC is designed to reduce activity of the epithelial sodium channel alpha subunit (ENaC) in the airways of the lung.
  • In patients with CF, CFTR dysfunction causes increased ENaC activity which contributes to airway dehydration and reduced mucociliary transport.

New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting

Retrieved on: 
Friday, June 12, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, Proteins, Branches of biology, Membrane proteins, Selectins, Biomarkers, Transmembrane receptors, Glycoproteins, E-selectin, P-selectin, Sickle Cell Disease (SCD) and VOC, Rivipansel, GMI-1687, GlycoMimetics, Inc.

This analysis and new biomarker data will be presented at the September meeting of the Foundation for Sickle Cell Disease Research (FSCDR).

Key Points: 
  • This analysis and new biomarker data will be presented at the September meeting of the Foundation for Sickle Cell Disease Research (FSCDR).
  • Furthermore, patients treated with rivipansel showed a statistically significant reduction in soluble E-selectin, a biomarker indicating that the drug had the intended biological effect.
  • Data from the RESET trial additionally demonstrate a safety profile for rivipansel comparable to the placebo.
  • In addition, the biomarker data showing reductions in soluble E-selectin indicates that rivipansel is hitting its intended biological target.